Search clinical trials for: best available therapy

Total 56959 results

Chinese PLA General Hospital
The General Hospital of Western Theater Command; First Hospital of China Medical... and other collaborators

Recruiting

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia

China
Merck Sharp & Dohme LLC

Recruiting

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Essential Thrombocythemia

Poland, Israel, Australia, Hong Kong, Japan, New Zealand, Taiwan, Korea, Republic of, United States, Spain, Italy, Netherlands
medac GmbH

Recruiting

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease (BALDER)

Steroid-refractory Acute Graft-versus-host Disease

Germany, Spain, France, Poland
Meiji Seika Pharma Co., Ltd.

Recruiting

P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales (Integral-2)

Acute Pyelonephritis | Complicated Intra-abdominal Infection | Complicated Urinary Tract Infection | Ventilator-associated Bacterial Pneumonia | Hospital-acquired Bacterial Pneumonia

Japan
Pfizer

Recruiting

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

Gram-negative Bacterial Infections

Spain, Taiwan, United States, Hungary, India, China, Turkey, Greece, Czechia
Institute of Hematology & Blood Diseases Hospital

Recruiting

TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

Connective Tissue Diseases | Autoantibodies | Immune Thrombocytopenia (ITP) | Evan Syndrome

China
Assistance Publique - Hôpitaux de Paris

Recruiting

A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia (ALLO-BEST)

Acute Myeloid Leukemia

France
VA Office of Research and Development

Recruiting

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (VA STARPORT)

Recurrent Prostate Cancer | Prostate Cancer | Metastatic Prostate Cancer | Oligometastasis | Oligorecurrence | De Novo Prostate Cancer

United States
medac GmbH

Recruiting

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy (IDUNN)

Steroid-refractory Acute Graft-versus-host Disease

Spain, Germany, France, Poland, Sweden
Geron Corporation

Recruiting

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Myelofibrosis

United States, Australia, Italy, India, United Kingdom, Israel, Taiwan, Poland, Malaysia, Argentina, Spain, Turkey, Belgium, Germany, Austria, Brazil, Bulgaria, Colombia, Denmark, France, Georgia, Hungary, Korea, Republic of, Portugal, ... and more
National Institute of Allergy and Infectious Diseases...
PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN); Blood...

Recruiting

Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (BEAT-MS)

Relapsing Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Kartos Therapeutics, Inc.

Recruiting

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera MF (Post-PV-MF) | Post-Essential Thrombocythemia MF (Post-ET-MF)

United States, Korea, Republic of, Germany, Australia, Hungary, France, Spain, Italy, Taiwan, Thailand, Brazil, Poland, Turkey, Israel, Portugal, Romania, Argentina, Bulgaria, Canada, Croatia, Czechia, Lithuania, Mexico, Philippines, United... and more
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Terminated

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Thailand, Malaysia, Korea, Republic of, Italy, United Kingdom, Poland, Germany, Turkey
AbbVie

Active, not recruiting

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

Myelofibrosis (MF)

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, Puerto Rico, Russian Federation, Serbia, South... and more
Sellas Life Sciences Group

Active, not recruiting

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (REGAL)

Acute Myeloid Leukemia

United States, Spain, France, Taiwan, India, Hungary, Poland, Germany, Serbia, Greece
The University of Queensland
Shionogi

Completed

RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI (GAMECHANGER)

Bloodstream Infections

Taiwan, Thailand, Singapore, Australia, Malaysia, Turkey
Pfizer
Allergan

Terminated

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

Serious Bacterial Infection

Romania, Taiwan, China, Malaysia, Thailand, Philippines, Argentina, Greece, India, United States, Mexico, Russian Federation
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

Leukemia, Chronic Myelogenous

China
Incyte Corporation

Completed

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Graft-versus-host Disease (GVHD)

Belgium, Italy, Spain, Saudi Arabia, Turkey, United Kingdom, Germany, Greece, Canada, Austria, France, Israel, Netherlands, Sweden, Switzerland, Korea, Republic of, Bulgaria, Japan, Norway, Czechia, Russian Federation, Jordan, Hungary, Ind... and more
Sierra Oncology, Inc.

Completed

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF (Simplify 2)

Primary Myelofibrosis (PMF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | Post-polycythemia Vera (Post-PV)

United States, Canada, France, Italy, Germany, Spain, Israel, United Kingdom
Maimónides Biomedical Research Institute of Córdoba

Completed

Calcifediol in the Treatment of COVID 19

COVID-19

Spain
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation (REACH2)

Corticosteroid Refractory Acute Graft vs Host Disease

Germany, Japan, Saudi Arabia, Turkey, United Kingdom, Spain, Canada, Italy, Australia, Austria, France, Korea, Republic of, Hong Kong, Israel, Netherlands, Russian Federation, Denmark, Greece, Taiwan, Norway, Czechia, Bulgaria
Hospital de Clinicas de Porto Alegre
Conselho Nacional de Desenvolvimento Científico e Tecnológico

Terminated

Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems (ABOVE)

Bloodstream Infection | Carbapenem-Resistant Enterobacteriaceae Infection

Brazil
Menarini Group

Terminated

Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections (DRESS)

Surgical Site Infection

Italy
Blueprint Medicines Corporation
Analysis Group, Inc.

Completed

Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM

Mast Cell Leukemia | Aggressive Systemic Mastocytosis | Advanced Systemic Mastocytosis | Systemic Mastocytosis With an Associated Hematological Neoplasm

United States, Austria, Germany, Spain, United Kingdom
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia (PAC326)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada, France, United Kingdom, Australia, Belgium, Germany, New Zealand, Netherlands, Russian Federation, Hungary, Czechia
Blueprint Medicines Corporation
Analysis Group, Inc.

Enrolling by invitation

External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

Neoplasms | Respiratory Tract Diseases | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Carcinoma | Neoplasms, Germ Cell and Embryonal | Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Bronchial Diseases | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Neoplasms... and other conditions

United States, France, Switzerland
Maimónides Biomedical Research Institute of Córdoba

Completed

Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria (CAVICOR)

Carbapenem-Resistant Enterobacteriaceae Infection

Spain
Novartis Pharmaceuticals

Completed

Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. (RESPONSE-2)

Polycythemia Vera

Hungary, Italy, Belgium, Germany, Spain, Korea, Republic of, Israel, Canada, Turkey, France, Australia, India
French Innovative Leukemia Organisation
Novartis Pharmaceuticals

Terminated

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

Essential Thrombocythemia

France
AOP Orphan Pharmaceuticals AG
PharmaEssentia Corporation (for the U.S.)

Completed

AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. (CONTI-PV)

Polycythemia Vera

Spain, Austria, Bulgaria, France, Germany, Hungary, Poland, Romania, Russian Federation, Slovakia, Ukraine, Czechia
Hospital Universitario Dr. Jose E. Gonzalez

Completed

Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia (COP-COVID-19)

Coronavirus Infection

Mexico
Shionogi

Completed

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens (CREDIBLE - CR)

Sepsis | Bloodstream Infections (BSI) | Hospital Acquired Pneumonia (HAP) | Complicated Urinary Tract Infection (cUTI) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)

United States, Brazil, Croatia, France, Germany, Greece, Guatemala, Israel, Italy, Japan, Korea, Republic of, Spain, Taiwan, Thailand, Turkey, United Kingdom
AO GENERIUM

Completed

Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19

COVID-19 | Coronavirus Disease 2019

Russian Federation
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Russian Federation, United Kingdom
University of Minnesota
National Institute of Mental Health (NIMH)

Completed

Effectiveness of Stepped Care Versus Best Available Care for Bulimia Nervosa

Eating Disorders

United States
Novartis Pharmaceuticals

Completed

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Myelofibrosis

France, United Kingdom, Belgium, Germany, Netherlands, Italy, Austria, Spain, Sweden
Incyte Corporation
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Polycythemia Vera

United States, Canada, France, Italy, United Kingdom, China, Belgium, Germany, Spain, Turkey, Japan, Australia, Korea, Republic of, Netherlands, Russian Federation, Argentina, Thailand, Hungary
Rempex (a wholly owned subsidiary of Melinta Therapeutics...
Department of Health and Human Services

Completed

Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults

Bacteremia | Acute Pyelonephritis | Ventilator-associated Bacterial Pneumonia | Urinary Tract Infection Complicated | Hospital Acquired Bacterial Pneumonia | Abdominal Infection

Italy, United States, Colombia, Greece, Israel, Brazil, Argentina, United Kingdom
Cell Medica Ltd
Wellcome Trust; EMAS Pharma; Commitum AB; BioAnaLab

Completed

Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study (CMV-IMPACT)

Cytomegalovirus Infection

United Kingdom
Pfizer
Forest Laboratories

Completed

Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

Complicated Intra-abdominal Infection | Complicated Urinary Tract Infection

Croatia, Bulgaria, Korea, Republic of, Mexico, Peru, Russian Federation, Spain, Turkey, Poland, Romania, Ukraine, South Africa, Argentina, Israel, United States, Philippines, France, Czechia
Jonsson Comprehensive Cancer Center

Not yet recruiting

PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma

Glioblastoma

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Evaluating the Impact of a Virtually Supervised Exercise Intervention and Group Counseling on Inflammation and the Microbiome of Smokers at High Risk for Lung Cancer, BE FIT Trial

Lung Carcinoma

United States
William Beaumont Hospitals

Recruiting

HYPOFRACTIONATED REGIONAL NODAL IRRADIATION IN BREAST CANCER

Breast Cancer

United States
M.D. Anderson Cancer Center

Not yet recruiting

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

Advanced Bladder Cancer

United States
Medical University of Vienna
Lund University; Ziekenhuis Netwerk Antwerpen (ZNA); St. Antonius Hospital; Azienda... and other collaborators

Not yet recruiting

Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study (OLIGOMET)

Prostate Cancer | Prostate Cancer Metastatic | Oligometastasis | Prostate Neoplasm | Oligometastatic Disease | Prostate Cancer Metastatic to Bone
M.D. Anderson Cancer Center

Not yet recruiting

Prospective Observational Cohort Study of Transplant and Cell Therapy Candidates and Recipients to Assess Social Determinants of Health

Transplant and Cell Therapy

United States
University of Southern California
National Cancer Institute (NCI)

Not yet recruiting

Access to Genetic Testing in Underserved Patients With Cancer

Malignant Solid Neoplasm | Breast Carcinoma | Metastatic Prostate Carcinoma | Ovarian Carcinoma | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Pancreatic Exocrine Neoplasm | Stage IVB Prostate Cancer American Joint Committee on Cancer v8

United States
Hebei Medical University Fourth Hospital

Not yet recruiting

Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

Search clinical trials for: best available therapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations